PRVA (Privia Health Group) Research & Development: $0 Mil (TTM As of Mar. 2026)


PRVA Privia Health Group Inc PRVA
85 GF Score
Price $25.73
GF Value $27.39
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Privia Health Group Research & Development?

Privia Health Group PRVA +0.67% 85 Research & Development is $0 Mil as of Mar. 2026. GuruFocus rates PRVA with a GF Score™ of 85/100 and a GF Value™ of $27.39 (Fairly Valued). The stock has 6 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Privia Health Group's Research & Development for the three months ended in Mar. 2026 was $0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $0 Mil.

Privia Health Group  (NAS:PRVA) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Privia Health Group Research & Development Related Terms

Privia Health Group Research & Development Historical Data

* Premium members only.

The historical data trend for Privia Health Group's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Privia Health Group Research & Development Chart

Privia Health Group Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Privia Health Group Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
PRVA
85GF Score
Privia Health Group Inc PRVA
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Privia Health Group Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $0 Mil mean?
Privia Health Group (PRVA) has a Research & Development of $0 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Privia Health Group and its competitors.
Is Privia Health Group's Research & Development too high?
Privia Health Group's current Research & Development is $0 Mil. Overall, Privia Health Group has a GF Score™ of 85/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Privia Health Group's Research & Development compare to HTFL and WAY?
Privia Health Group's Research & Development of $0 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Healthcare Providers & Services company?
A good Research & Development depends on the Healthcare Providers & Services industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Privia Health Group and its competitors. Privia Health Group's current Research & Development is $0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Privia Health Group stock overvalued right now?
Based on GuruFocus' analysis, Privia Health Group (PRVA) is currently considered Fairly Valued. The stock's GF Value™ is $27.39, compared to a current price of $25.73 — trading 6.1% below its estimated fair value. The current Research & Development is $0 Mil. Privia Health Group's overall GF Score™ is 85/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Privia Health Group (PRVA), the current Research & Development is $0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Privia Health Group (PRVA) Overvalued in 2026?

Based on GuruFocus' analysis, Privia Health Group stock appears to be undervalued. The current stock price of $25.73 is trading 6.1% below its estimated GF Value™ of $27.39. GuruFocus considers Privia Health Group to be Fairly Valued.

Key valuation signals for PRVA:

  • Research & Development: $0 Mil
  • GF Value™: $27.39 vs. price of $25.73 (6.1% below fair value)
  • GF Score™: 85/100 with 6 warning signs

No single metric tells the full story. See the PRVA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Privia Health Group Business Description

Address 950 North Glebe Road, Suite 700, Arlington, VA, USA, 22203
Privia Health Group Inc is one of the physician enablement companies in the United States with a presence in around 24 states and the District of Columbia. The group builds scaled provider networks with primary-care centric medical groups, risk-bearing entities, a physician-led governance structure, and the Privia Platform comprising an extensive suite of technology and service solutions. It collaborates with medical groups, health plans, and health systems to optimize approximately 1,300+ physician practices, improve the patient experience for over 5.8+ million patients, and reward around 5,300+ physicians and practitioners for delivering high-value care.
85GF Score

Get the complete analysis for PRVA

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$25.73
Price
$27.39
GF Value